Taro Pharma (TARO) Reports Q4 EPS of $3.42
Tweet
Share
E-mailGet Alerts TARO Hot Sheet
Join SI Premium – FREE
Taro Pharma (NYSE: TARO) reported Q4 EPS of $3.42, versus $4.41 reported last year. Revenue for the quarter came in at $220.4 million, versus $258.3 thousand reported last year.
For earnings history and earnings-related data on Taro Pharma (TARO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rivian reports record Q3 deliveries, beats estimates, shares rise
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- Robinhood shares climb on summit momentum and analyst support
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
